Is There an Interplay between Immune Checkpoint Inhibitors, Thromboprophylactic Treatments and Thromboembolic Events? Mechanisms and Impact in Non-Small Cell Lung Cancer Patients.

aspirin immune checkpoint inhibitors immunotherapy non-small cell lung cancer thromboembolic events thromboprophylaxis

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
25 Dec 2019
Historique:
received: 02 12 2019
revised: 19 12 2019
accepted: 20 12 2019
entrez: 29 12 2019
pubmed: 29 12 2019
medline: 29 12 2019
Statut: epublish

Résumé

PD-1 pathway blockade has been shown to promote proatherogenic T-cell responses and destabilization of atherosclerotic plaques. Moreover, preclinical evidence suggests a potential synergy of antiplatelet drugs with immune checkpoint inhibitors (ICIs). We conducted an analysis within a prospective observational protocol (APOLLO study) to investigate the rates, predictors, and prognostic significance of thromboembolic events (TE) and thromboprophylaxis in patients with advanced NSCLC treated with ICIs. Among 217 patients treated between April 2014 and September 2018, 13.8% developed TE events. Current smoking status (HR 3.61 (95% CI 1.52-8.60),

Identifiants

pubmed: 31881699
pii: cancers12010067
doi: 10.3390/cancers12010067
pmc: PMC7016680
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
Cancer Manag Res. 2017 Nov 30;9:741-750
pubmed: 29238224
J Clin Oncol. 2015 Jan 10;33(2):189-94
pubmed: 25452446
J Thorac Oncol. 2019 Apr;14(4):596-605
pubmed: 30543838
Arch Intern Med. 2006 Feb 27;166(4):458-64
pubmed: 16505267
J Clin Oncol. 2011 Nov 10;29(32):4320-6
pubmed: 21990410
Cancer Immunol Res. 2017 Aug;5(8):695-709
pubmed: 28765120
J Transl Med. 2017 Feb 23;15(1):46
pubmed: 28231855
Nature. 2019 May;569(7754):73-78
pubmed: 30996346
Nat Rev Clin Oncol. 2019 Jul;16(7):425-441
pubmed: 30914826
N Engl J Med. 2017 Nov 16;377(20):1919-1929
pubmed: 28885881
Lancet Oncol. 2009 Oct;10(10):943-9
pubmed: 19726226
Target Oncol. 2018 Aug;13(4):509-515
pubmed: 30006825
J Thromb Haemost. 2004 Oct;2(10):1760-5
pubmed: 15456487
Blood. 2008 May 15;111(10):4902-7
pubmed: 18216292
Lancet. 2016 Apr 9;387(10027):1540-1550
pubmed: 26712084
Ann Oncol. 2018 Feb 1;29(2):398-404
pubmed: 29106448
Crit Rev Oncol Hematol. 2007 Mar;61(3):195-207
pubmed: 17074500
Lancet Oncol. 2018 Sep;19(9):e447-e458
pubmed: 30191849
Lung Cancer. 2012 Dec;78(3):253-8
pubmed: 23026639
N Engl J Med. 2018 Nov 22;379(21):2040-2051
pubmed: 30280635
J Clin Oncol. 2017 Jun 1;35(16):1836-1844
pubmed: 28406723
N Engl J Med. 2019 Feb 21;380(8):711-719
pubmed: 30511879
Eur Respir J. 2018 May 3;51(5):
pubmed: 29563169
N Engl J Med. 2019 Feb 21;380(8):720-728
pubmed: 30786186
N Engl J Med. 2016 Nov 10;375(19):1823-1833
pubmed: 27718847
Lancet Oncol. 2018 Apr;19(4):521-536
pubmed: 29545095
Clin Cancer Res. 2001 Sep;7(9):2669-74
pubmed: 11555578
Oncologist. 2013;18(12):1321-9
pubmed: 24212499
Lancet. 2017 Jan 21;389(10066):255-265
pubmed: 27979383
Blood. 2019 Feb 21;133(8):781-789
pubmed: 30578253
N Engl J Med. 2015 Oct 22;373(17):1627-39
pubmed: 26412456
J Pharmacol Exp Ther. 2019 Mar;368(3):401-413
pubmed: 30591531
Nat Rev Clin Oncol. 2019 Sep;16(9):563-580
pubmed: 31092901
Clin Cancer Res. 2019 Mar 1;25(5):1650-1663
pubmed: 30538110
BMC Cancer. 2010 Aug 30;10:464
pubmed: 20804550
J Clin Oncol. 2016 Feb 10;34(5):488-94
pubmed: 26700124
Br J Cancer. 2017 Mar 14;116(6):e1
pubmed: 27802452
Proc Natl Acad Sci U S A. 2017 Jan 31;114(5):1117-1122
pubmed: 28096371
JAMA Oncol. 2019 Jun 6;:
pubmed: 31169896
N Engl J Med. 2018 May 31;378(22):2078-2092
pubmed: 29658856
Respir Res. 2018 May 9;19(1):88
pubmed: 29743116
J Clin Oncol. 2017 Jul 1;35(19):2184-2192
pubmed: 28489511
Arterioscler Thromb Vasc Biol. 2011 May;31(5):1100-7
pubmed: 21393583
N Engl J Med. 2015 Jul 9;373(2):123-35
pubmed: 26028407
Eur J Cancer. 2018 Mar;91:164-166
pubmed: 29289455
Oncol Lett. 2018 Jan;15(1):552-558
pubmed: 29285200
JAMA Oncol. 2019 Jul 1;5(7):1008-1019
pubmed: 31021376
Thorax. 2013 May;68(5):442-50
pubmed: 23321607
Cancer Res. 2005 Jun 15;65(12):5211-20
pubmed: 15958566
Ann Oncol. 2017 Nov 1;28(11):2893-2895
pubmed: 28651328
Anticancer Res. 2018 Aug;38(8):4637-4644
pubmed: 30061230
Intern Emerg Med. 2012 Jun;7(3):291-2
pubmed: 22547369
Cell. 2015 Sep 10;162(6):1257-70
pubmed: 26343581
Thromb Haemost. 2018 Nov;118(11):1875-1884
pubmed: 30296815
PLoS One. 2014 Apr 01;9(4):e93280
pubmed: 24691202

Auteurs

Federico Nichetti (F)

Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy.

Francesca Ligorio (F)

Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy.

Emma Zattarin (E)

Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy.

Diego Signorelli (D)

Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy.

Arsela Prelaj (A)

Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy.

Claudia Proto (C)

Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy.

Giulia Galli (G)

Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy.

Antonio Marra (A)

Department of Medical Oncology, Istituto Europeo di Oncologia, 20141 Milan, Italy.

Giulia Apollonio (G)

Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy.

Luca Porcu (L)

Department of Oncology, IRCCS Istituto di Ricerche Farmacologiche Mario Negri, 20156 Milan, Italy.

Filippo de Braud (F)

Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy.
Department of Oncology and Hemato-Oncology, University of Milan, 20122 Milan, Italy.

Giuseppe Lo Russo (G)

Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy.

Roberto Ferrara (R)

Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy.

Marina Chiara Garassino (MC)

Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy.

Classifications MeSH